Cat. No.: HY-13716

Noscapine

(Synonyms: (S,R)-Noscapine)

2 Cited Publications

Customer Review

Based on 2 publication(s) in Google Scholar

Noscapine ((S,R)-Noscapine) is an orally active phthalideisoquinoline alkaloid with potent antitussive. Noscapine exerts its antitussive effects by activating sigma opioid receptors and is a non-competitive Bradykinin inhibitor. Noscapine disrupts microtubule dynamics, induces mitotic arrest and apoptosis. Noscapine possesses anticancer, neuroprotective, anti-inflammatory activities, and can cross the blood-brain barrier.

For research use only. We do not sell to patients.

Purity: 99.98%
CAS No.: 128-62-1
Formula: C₂₂H₂₃NO₇
Molecular Weight:413.42

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

Noscapine Chemical Structure

CAS No.: 128-62-1

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (2)
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

IC₅₀ & Target

Sigma opioid receptors^[4] Bradykinin^[5] Apoptosis^[1]

All Opioid Receptor Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
A 172	IC₅₀	20 μM Compound: 6	Antiproliferative activity against human A172 cells assessed as decrease in colony formation Antiproliferative activity against human A172 cells assessed as decrease in colony formation	[PMID: 25811651]
A-375	IC₅₀	180.1 μM Compound: Noscapine	Cytotoxicity against human A-375 cells measured for 48 hrs Cytotoxicity against human A-375 cells measured for 48 hrs	[PMID: 38823729]
A549	EC₅₀	25 μM Compound: 1, noscapine	Effect on cell growth in A549 cells by MTS assay Effect on cell growth in A549 cells by MTS assay	[PMID: 16279766]
A549	IC₅₀	65.2 μM Compound: Noscapine	Inhibition of NF-kappaB activation in human TNFalpha-stimulated A549 cells preincubated for 2 hrs before TNFalpha challenge measured after 7 hrs post stimulation by luciferase reporter gene assay Inhibition of NF-kappaB activation in human TNFalpha-stimulated A549 cells preincubated for 2 hrs before TNFalpha challenge measured after 7 hrs post stimulation by luciferase reporter gene assay	[PMID: 22137846]
A549	IC₅₀	62.9 μM Compound: 1	Antiproliferative activity against human A549 cells after 72 hrs by MTS assay Antiproliferative activity against human A549 cells after 72 hrs by MTS assay	[PMID: 25453814]
A549	IC₅₀	72.9 μM Compound: 6	Cytotoxicity against human A549 cells Cytotoxicity against human A549 cells	[PMID: 25811651]
Bel-7402	IC₅₀	>1000 nM Compound: 1	Antiproliferative activity against human Bel7402 after 72 hrs by CellTiter Glo assay Antiproliferative activity against human Bel7402 after 72 hrs by CellTiter Glo assay	[PMID: 22320354]
CCRF-CEM	IC₅₀	14.5 μM Compound: 6	Cytotoxicity against human CEM cells Cytotoxicity against human CEM cells	[PMID: 25811651]
HCT-116	IC₅₀	153.8 μM Compound: Noscapine	Cytotoxicity against human HCT-116 cells measured for 48 hrs Cytotoxicity against human HCT-116 cells measured for 48 hrs	[PMID: 38823729]
HEK293	IC₅₀	2.6 μM Compound: noscapine	Inhibition of human OCT2-mediated ASP+ uptake expressed in HEK293 cells after 3 mins by fluorescence assay Inhibition of human OCT2-mediated ASP+ uptake expressed in HEK293 cells after 3 mins by fluorescence assay	[PMID: 23241029]
HEK293	IC₅₀	34.5 μM Compound: noscapine	Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay	[PMID: 23241029]
HeLa	IC₅₀	24 μM Compound: 1	Antiproliferative activity against human HeLa cells after 72 hrs by MTS assay Antiproliferative activity against human HeLa cells after 72 hrs by MTS assay	[PMID: 25453814]
HeLa	EC₅₀	18.4 μM Compound: 6	Antimitotic activity against human HeLa cells Antimitotic activity against human HeLa cells	[PMID: 25811651]
HeLa	IC₅₀	24 μM Compound: 6	Cytotoxicity against human HeLa cells Cytotoxicity against human HeLa cells	[PMID: 25811651]
HeLa	IC₅₀	25 μM Compound: 5	Cytotoxicity against human HeLa cells Cytotoxicity against human HeLa cells	[PMID: 30156410]
HeLa	IC₅₀	25 μM Compound: 1	Antiproliferative activity against human HeLa cells assessed as inhibition of cell proliferation Antiproliferative activity against human HeLa cells assessed as inhibition of cell proliferation	[PMID: 38352836]
Hep 3B2	IC₅₀	>1000 nM Compound: 1	Antiproliferative activity against human Hep3B after 72 hrs by CellTiter Glo assay Antiproliferative activity against human Hep3B after 72 hrs by CellTiter Glo assay	[PMID: 22320354]
HepG2	IC₅₀	>1000 nM Compound: 1	Antiproliferative activity against human HepG2 after 72 hrs by CellTiter Glo assay Antiproliferative activity against human HepG2 after 72 hrs by CellTiter Glo assay	[PMID: 22320354]
HepG2	IC₅₀	120.3 μM Compound: Noscapine	Cytotoxicity against human HepG2 cells measured for 48 hrs Cytotoxicity against human HepG2 cells measured for 48 hrs	[PMID: 38823729]
Huh-7	IC₅₀	>1000 nM Compound: 1	Antiproliferative activity against human HuH7 after 72 hrs by CellTiter Glo assay Antiproliferative activity against human HuH7 after 72 hrs by CellTiter Glo assay	[PMID: 22320354]
JeKo-1	IC₅₀	>20 μM Compound: 1	Antiproliferative activity against human JeKo-1 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK8 assay Antiproliferative activity against human JeKo-1 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK8 assay	[PMID: 38352836]
LN-229	IC₅₀	70 μM Compound: 6	Antiproliferative activity against human LN229 cells assessed as decrease in colony formation Antiproliferative activity against human LN229 cells assessed as decrease in colony formation	[PMID: 25811651]
MCF7	IC₅₀	57 μM Compound: Noscapine	Cytotoxicity against human MCF7 cells assessed as growth inhibition after 48 hrs by methylene blue staining-based assay Cytotoxicity against human MCF7 cells assessed as growth inhibition after 48 hrs by methylene blue staining-based assay	[PMID: 25240616]
MCF7	IC₅₀	42.3 μM Compound: 1	Antiproliferative activity against human MCF7 cells after 72 hrs by MTS assay Antiproliferative activity against human MCF7 cells after 72 hrs by MTS assay	[PMID: 25453814]
MCF7	IC₅₀	42.3 μM Compound: 6	Cytotoxicity against human MCF7 cells Cytotoxicity against human MCF7 cells	[PMID: 25811651]
MCF7	IC₅₀	18.8 μM Compound: 5	Antiproliferative activity against human MCF7 cells after 6 days by MTT assay Antiproliferative activity against human MCF7 cells after 6 days by MTT assay	[PMID: 30156410]
MCF7	IC₅₀	42 μM Compound: 5	Cytotoxicity against human MCF7 cells Cytotoxicity against human MCF7 cells	[PMID: 30156410]
MCF7	IC₅₀	42 μM Compound: 1	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell proliferation Antiproliferative activity against human MCF7 cells assessed as inhibition of cell proliferation	[PMID: 38352836]
MDA-MB-231	IC₅₀	64 μM Compound: Noscapine	Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 48 hrs by methylene blue staining-based assay Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 48 hrs by methylene blue staining-based assay	[PMID: 25240616]
MDA-MB-231	IC₅₀	120.3 μM Compound: Noscapine	Cytotoxicity against human MDA-MB-231 cells measured for 48 hrs Cytotoxicity against human MDA-MB-231 cells measured for 48 hrs	[PMID: 38823729]
MHCC97H	IC₅₀	>1000 nM Compound: 1	Antiproliferative activity against human MHCC97H after 72 hrs by CellTiter Glo assay Antiproliferative activity against human MHCC97H after 72 hrs by CellTiter Glo assay	[PMID: 22320354]
MOLM-13	IC₅₀	>20 μM Compound: 1	Antiproliferative activity against human MOLM-13 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK8 assay Antiproliferative activity against human MOLM-13 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK8 assay	[PMID: 38352836]
NB-4	IC₅₀	>20 μM Compound: 1	Antiproliferative activity against human NB4 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK8 assay Antiproliferative activity against human NB4 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK8 assay	[PMID: 38352836]
NCI/ADR-RES	IC₅₀	17.4 μM Compound: 5	Antiproliferative activity against human NCI/ADR-RES cells after 6 days by MTT assay Antiproliferative activity against human NCI/ADR-RES cells after 6 days by MTT assay	[PMID: 30156410]
NCI-H460	IC₅₀	34.7 μM Compound: 6	Cytotoxicity against human H460 cells after 72 hrs Cytotoxicity against human H460 cells after 72 hrs	[PMID: 25811651]
PLC-PRF-5	IC₅₀	>1000 nM Compound: 1	Antiproliferative activity against human PLC/PRF/5 after 72 hrs by CellTiter Glo assay Antiproliferative activity against human PLC/PRF/5 after 72 hrs by CellTiter Glo assay	[PMID: 22320354]
PLC-PRF-5	IC₅₀	>2000 nM Compound: 1	Antiproliferative activity against human PLC/PRF/5 cells Antiproliferative activity against human PLC/PRF/5 cells	[PMID: 22320354]
SH-SY5Y	IC₅₀	80.3 μM Compound: Noscapine	Cytotoxicity against human SH-SY5Y cells after 48 hrs by MTT assay Cytotoxicity against human SH-SY5Y cells after 48 hrs by MTT assay	[PMID: 25728023]
SMMC-7721	IC₅₀	>1000 nM Compound: 1	Antiproliferative activity against human SMMC7721 after 72 hrs by CellTiter Glo assay Antiproliferative activity against human SMMC7721 after 72 hrs by CellTiter Glo assay	[PMID: 22320354]
SNU-182	IC₅₀	>1000 nM Compound: 1	Antiproliferative activity against human SNU182 after 72 hrs by CellTiter Glo assay Antiproliferative activity against human SNU182 after 72 hrs by CellTiter Glo assay	[PMID: 22320354]
SNU-387	IC₅₀	>1000 nM Compound: 1	Antiproliferative activity against human SNU387 after 72 hrs by CellTiter Glo assay Antiproliferative activity against human SNU387 after 72 hrs by CellTiter Glo assay	[PMID: 22320354]
SNU-398	IC₅₀	>1000 nM Compound: 1	Antiproliferative activity against human SNU398 after 72 hrs by CellTiter Glo assay Antiproliferative activity against human SNU398 after 72 hrs by CellTiter Glo assay	[PMID: 22320354]
SNU-398	IC₅₀	>2000 nM Compound: 1	Antiproliferative activity against human SNU398 cells Antiproliferative activity against human SNU398 cells	[PMID: 22320354]
SNU-423	IC₅₀	>1000 nM Compound: 1	Antiproliferative activity against human SNU423 after 72 hrs by CellTiter Glo assay Antiproliferative activity against human SNU423 after 72 hrs by CellTiter Glo assay	[PMID: 22320354]
SNU-449	IC₅₀	>1000 nM Compound: 1	Antiproliferative activity against human SNU449 after 72 hrs by CellTiter Glo assay Antiproliferative activity against human SNU449 after 72 hrs by CellTiter Glo assay	[PMID: 22320354]
SNU-475	IC₅₀	>1000 nM Compound: 1	Antiproliferative activity against human SNU475 after 72 hrs by CellTiter Glo assay Antiproliferative activity against human SNU475 after 72 hrs by CellTiter Glo assay	[PMID: 22320354]
U-251	IC₅₀	40 μM Compound: 6	Antiproliferative activity against human U251 cells assessed as decrease in colony formation Antiproliferative activity against human U251 cells assessed as decrease in colony formation	[PMID: 25811651]

In Vitro

Noscapine (0-1000 μM; 0-96 hours; rat C6 glioma cells) treatment inhibits cell viability of rat C6 glioma in vitro in a dose- and time-dependent manner. Noscapine inhibits the viability of rat C6 glioma cells with an IC₅₀ of 250 μM at 72 hours^[1].
Noscapine exposure causes abnormal S-phase reentry, increases mitotic arrest and results in excessive DNA accumulation^[1].
Cylindromatosis increases the ability of noscapine to induce mitotic arrest and apoptosis. Cylindromatosis enhances the effect of noscapine on microtubule polymerization and promotes noscapine binding to microtubules^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:

Rat C6 glioma cells
Concentration:

0 μM, 0.1 μM, 1 μM, 2 μM, 10 μM, 50 μM, 100 μM, 1000 μM
Incubation Time:

0 hours, 12 hours, 24 hours, 48 hours, 72 hours, 96 hours
Result:

Inhibited cell viability of rat C6 glioma in vitro in a dose- and time-dependent manner.

In Vivo

To ensure solubility, animal experiments can choose Noscapine hydrochloride (HY-13716A):
Noscapine hydrochloride (300 mg/kg; oral gavage; daily; for 15 days; athymic female mice) treatment reduces tumor growth in mice^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Athymic female mice (nu/nu) (8-week-old) injected with rat C6 glioma cells^[1]
Dosage:

300 mg/kg
Administration:

Oral gavage; daily; for 15 days
Result:

Revealed a significant reduction of tumor volume.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS No. 128-62-1
Appearance Solid
Molecular Weight 413.42
Formula C₂₂H₂₃NO₇
Color White to off-white
SMILES

O=C1O[C@H]([C@@H]2N(C)CCC3=C2C(OC)=C(OCO4)C4=C3)C5=C1C(OC)=C(OC)C=C5
Synonyms

(S,R)-Noscapine
Structure Classification
- Alkaloids
- Quinoline Alkaloids
Initial Source
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (2)

All

Sort by:

Journal Impact Factor

Cancer Biomark

TUBB3 (βIII-tubulin) drives gastric cancer progression and poor prognosis by regulating cell cycle and invadopodia formation. [Abstract]

2025 Oct;42(10):18758592251390145. PMID: 41129675
Patent

US20180263995A1.

Solvent & Solubility

In Vitro:

DMSO : ≥ 30 mg/mL (72.57 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.4188 mL

12.0942 mL

24.1885 mL

5 mM

0.4838 mL

2.4188 mL

4.8377 mL

10 mM

0.2419 mL

1.2094 mL

2.4188 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (6.05 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (6.05 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (284 KB)
SDS (392 KB)
- English - EN (392 KB)
- Français - FR (392 KB)
- Deutsch - DE (392 KB)
- Norwegian - NO (392 KB)
- Español - ES (392 KB)
- Swedish - SV (392 KB)
- Italian - IT (392 KB)
- Korean - KR (392 KB)
- Portuguese - PT (392 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Jaren W Landen, et al. Noscapine Crosses the Blood-Brain Barrier and Inhibits Glioblastoma Growth. Clin Cancer Res. 2004 Aug 1;10(15):5187-201. [Content Brief]

[2]. Yunfan Yang, et al. CYLD Regulates Noscapine Activity in Acute Lymphoblastic Leukemia via a Microtubule-Dependent Mechanism. Theranostics. 2015 Mar 2;5(7):656-66. [Content Brief]

[3]. Vartika Tomar, et al. Noscapine and Its Analogs as Chemotherapeutic Agent: Current Updates. Curr Top Med Chem. 2017;17(2):174-188. [Content Brief]

[4]. Bianca Lokhorst, et al. Interaction of OTC Drug Noscapine and Acenocoumarol and Phenprocoumon. Br J Clin Pharmacol. 2019 May;85(5):1041-1043. [Content Brief]

[5]. S A Ebrahimi, et al. Interaction of Noscapine With the Bradykinin Mediation of the Cough Response. Acta Physiol Hung. 2003;90(2):147-55. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.4188 mL	12.0942 mL	24.1885 mL	60.4712 mL
	5 mM	0.4838 mL	2.4188 mL	4.8377 mL	12.0942 mL
	10 mM	0.2419 mL	1.2094 mL	2.4188 mL	6.0471 mL
	15 mM	0.1613 mL	0.8063 mL	1.6126 mL	4.0314 mL
	20 mM	0.1209 mL	0.6047 mL	1.2094 mL	3.0236 mL
	25 mM	0.0968 mL	0.4838 mL	0.9675 mL	2.4188 mL
	30 mM	0.0806 mL	0.4031 mL	0.8063 mL	2.0157 mL
	40 mM	0.0605 mL	0.3024 mL	0.6047 mL	1.5118 mL
	50 mM	0.0484 mL	0.2419 mL	0.4838 mL	1.2094 mL
	60 mM	0.0403 mL	0.2016 mL	0.4031 mL	1.0079 mL

Keywords

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Noscapine

Apoptosis Compound Library

GPCR/G Protein Compound Library

Neuronal Signaling Compound Library

Natural Product Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Drug Repurposing Compound Library

Orally Active Compound Library

Neurotransmitter Receptor Compound Library

Traditional Chinese Medicine Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Neuroprotective Compound Library

Alkaloids Library

Food-Sourced Compound Library

Targeted Diversity Library

Rare Diseases Drug Library

Anti-Cancer Natural Product Library

Antidepressant Compound Library

Plant-Sourced Natural Product Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Pain-Related Compound Library

Off-patent Drug Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Cell Death Library

FDA-Approved Traditional Chinese Medicine Active Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Flavor Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Mass Spectrometry Human Metabolite Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Mongolian Medicine Compound Library

Natural Product Diversity Scaffold Library

Lactylation Compound Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) Noscapine

All Opioid Receptor Isoforms

Biological Activity

Chemical Information

Publications (2)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Noscapine Related Classifications

HY-13716 Related Classifications